Comparison Overview

Chugai Pharma USA, Inc.

VS

Cipla

Chugai Pharma USA, Inc.

JP
Last Update: 2025-12-10
View Profile
Between 800 and 849
http://www.chugai-pharm.co.jp/hc/ss/english/index.html

Chugai’s strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai-originated, innovative new drug candidates. Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties. For a list of Chugai’s current research projects please visit: http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 227
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Cipla

Lower Parel, Ganpatrao Kadam Marg,, Mumbai, Maharashtra, IN, 400013
Last Update: 2025-12-09
Between 750 and 799
http://www.cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 49,702
Subsidiaries: 7
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/chugai-pharmaceutical-co--ltd-.jpeg
Chugai Pharma USA, Inc.
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Chugai Pharma USA, Inc.
100%
Compliance Rate
0/4 Standards Verified
Cipla
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Chugai Pharma USA, Inc. in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Cipla in 2025.

Incident History — Chugai Pharma USA, Inc. (X = Date, Y = Severity)

Chugai Pharma USA, Inc. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Cipla (X = Date, Y = Severity)

Cipla cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/chugai-pharmaceutical-co--ltd-.jpeg
Chugai Pharma USA, Inc.
Incidents

No Incident

https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
Incidents

No Incident

FAQ

Chugai Pharma USA, Inc. company demonstrates a stronger AI Cybersecurity Score compared to Cipla company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Cipla company has disclosed a higher number of cyber incidents compared to Chugai Pharma USA, Inc. company.

In the current year, Cipla company and Chugai Pharma USA, Inc. company have not reported any cyber incidents.

Neither Cipla company nor Chugai Pharma USA, Inc. company has reported experiencing a ransomware attack publicly.

Neither Cipla company nor Chugai Pharma USA, Inc. company has reported experiencing a data breach publicly.

Neither Cipla company nor Chugai Pharma USA, Inc. company has reported experiencing targeted cyberattacks publicly.

Neither Chugai Pharma USA, Inc. company nor Cipla company has reported experiencing or disclosing vulnerabilities publicly.

Neither Chugai Pharma USA, Inc. nor Cipla holds any compliance certifications.

Neither company holds any compliance certifications.

Cipla company has more subsidiaries worldwide compared to Chugai Pharma USA, Inc. company.

Cipla company employs more people globally than Chugai Pharma USA, Inc. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Chugai Pharma USA, Inc. nor Cipla holds SOC 2 Type 1 certification.

Neither Chugai Pharma USA, Inc. nor Cipla holds SOC 2 Type 2 certification.

Neither Chugai Pharma USA, Inc. nor Cipla holds ISO 27001 certification.

Neither Chugai Pharma USA, Inc. nor Cipla holds PCI DSS certification.

Neither Chugai Pharma USA, Inc. nor Cipla holds HIPAA certification.

Neither Chugai Pharma USA, Inc. nor Cipla holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
References
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
References
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N
References